185 related articles for article (PubMed ID: 36853491)
1. CircOMA1 modulates cabergoline resistance by downregulating ferroptosis in prolactinoma.
Wu N; Zhu D; Li J; Li X; Zhu Z; Rao Q; Hu B; Wang H; Zhu Y
J Endocrinol Invest; 2023 Aug; 46(8):1573-1587. PubMed ID: 36853491
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
[TBL] [Abstract][Full Text] [Related]
3. miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma.
Hu B; Mao Z; Du Q; Jiang X; Wang Z; Xiao Z; Zhu D; Wang X; Zhu Y; Wang H
Brain Res Bull; 2019 Jul; 149():21-31. PubMed ID: 30946881
[TBL] [Abstract][Full Text] [Related]
4. Phenotype and resistance patterns of 10 resistant prolactinomas.
Araujo-Castro M; Abad López A; Aller Pardo J; Kanaan Kanaan L; Palacios García N
Endocrinol Diabetes Nutr (Engl Ed); 2020 Mar; 67(3):194-204. PubMed ID: 31201099
[TBL] [Abstract][Full Text] [Related]
5. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
6. microRNA expression profile and differentially-expressed genes in prolactinomas following bromocriptine treatment.
Wang C; Su Z; Sanai N; Xue X; Lu L; Chen Y; Wu J; Zheng W; Zhuge Q; Wu ZB
Oncol Rep; 2012 May; 27(5):1312-20. PubMed ID: 22366961
[TBL] [Abstract][Full Text] [Related]
7. The KBTBD6/7-DRD2 axis regulates pituitary adenoma sensitivity to dopamine agonist treatment.
Liu YT; Liu F; Cao L; Xue L; Gu WT; Zheng YZ; Tang H; Wang Y; Yao H; Zhang Y; Xie WQ; Ren BH; Xiao ZH; Nie YJ; Hu R; Wu ZB
Acta Neuropathol; 2020 Sep; 140(3):377-396. PubMed ID: 32572597
[TBL] [Abstract][Full Text] [Related]
8. Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs.
Cheng J; Xie W; Chen Y; Sun Y; Gong L; Wang H; Li C; Zhang Y
Drug Resist Updat; 2024 Mar; 73():101056. PubMed ID: 38277755
[TBL] [Abstract][Full Text] [Related]
9. Management of Dopamine Agonist-Resistant Prolactinoma.
Maiter D
Neuroendocrinology; 2019; 109(1):42-50. PubMed ID: 30481756
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in Dopamine Agonist-Resistant Prolactinoma.
Wan X; Yan Z; Tan Z; Cai Z; Qi Y; Lu L; Xu Y; Chen J; Lei T
Neuroendocrinology; 2022; 112(5):417-426. PubMed ID: 34034260
[TBL] [Abstract][Full Text] [Related]
11. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
Tang C; Sun R; Wen G; Zhong C; Yang J; Zhu J; Cong Z; Luo X; Ma C
Cell Death Dis; 2019 Apr; 10(5):335. PubMed ID: 31000722
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Prolactinoma.
Inder WJ; Jang C
Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013562
[TBL] [Abstract][Full Text] [Related]
13. Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment.
Pirchio R; Auriemma RS; Solari D; Arnesi M; Pivonello C; Negri M; de Angelis C; Cavallo LM; Cappabianca P; Colao A; Pivonello R
Front Endocrinol (Lausanne); 2021; 12():769744. PubMed ID: 34917030
[TBL] [Abstract][Full Text] [Related]
14. DEPTOR inhibits cell proliferation and confers sensitivity to dopamine agonist in pituitary adenoma.
Yao H; Tang H; Zhang Y; Zhang QF; Liu XY; Liu YT; Gu WT; Zheng YZ; Shang HB; Wang Y; Huang JY; Wei YX; Zhang X; Zhang J; Wu ZB
Cancer Lett; 2019 Sep; 459():135-144. PubMed ID: 31176743
[TBL] [Abstract][Full Text] [Related]
15. The long noncoding RNA-H19/miRNA-93a/ATG7 axis regulates the sensitivity of pituitary adenomas to dopamine agonists.
Wu Z; Zheng Y; Xie W; Li Q; Zhang Y; Ren B; Cai L; Cheng Y; Tang H; Su Z; Wu ZB
Mol Cell Endocrinol; 2020 Dec; 518():111033. PubMed ID: 32946927
[TBL] [Abstract][Full Text] [Related]
16. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
18. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas.
Fusco A; Gunz G; Jaquet P; Dufour H; Germanetti AL; Culler MD; Barlier A; Saveanu A
Eur J Endocrinol; 2008 May; 158(5):595-603. PubMed ID: 18426817
[TBL] [Abstract][Full Text] [Related]
19. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
20. Resistant prolactinomas: a case series of 26 patients.
Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
